fingolimod hydrochloride has been researched along with Obesity in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Blecharz-Klin, K; Mirowska-Guzel, D; Piechal, A; Pyrzanowska, J; Strosznajder, RP; Wencel, PL | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Cui, H; Gu, C; Kim, LJ; Lee, R; Mitrut, R; Pham, L; Polotsky, VY; Sham, JSK; Shin, MK; Tang, WY; Yeung, BHY | 1 |
| Hait, NC; Katsuta, E; Lyon, DE; Nagahashi, M; Rashid, OM; Raza, A; Sturgill, JL; Takabe, K; Yan, L | 1 |
| Abe, M; Allegood, JC; Aoyagi, T; Hait, NC; Huang, WC; Katsuta, E; Milstien, S; Nagahashi, M; Nakajima, M; Sakimura, K; Spiegel, S; Takabe, K; Terracina, KP; Tsuchida, J; Wakai, T; Yamada, A; Yuza, K | 1 |
| Cooper, BE; Ezzyat, Y; Fielding, RA; McDonald, DJ; Rice, NP; Rivas, DA | 1 |
| Gao, M; Liu, D; Qu, S; Song, K; Yan, L | 1 |
| Jeong, JK; Lee, JH; Lee, YJ; Moon, MH; Park, SY; Park, YG; Seol, JW | 1 |
| Babb, JR; Bruce, CR; Febbraio, MA; Henstridge, DC; Lee-Young, RS; Risis, S; Yang, C | 1 |
9 other study(ies) available for fingolimod hydrochloride and Obesity
| Article | Year |
|---|---|
Fingolimod Modulates the Gene Expression of Proteins Engaged in Inflammation and Amyloid-Beta Metabolism and Improves Exploratory and Anxiety-Like Behavior in Obese Mice.
Topics: Amyloid Precursor Protein Secretases; Animals; Anxiety; Aspartic Acid Endopeptidases; bcl-2-Associated X Protein; Cytokines; Diabetes Mellitus, Type 2; Fingolimod Hydrochloride; Gene Expression; Inflammation; Mice; Mice, Obese; Obesity; Receptors, Lysosphingolipid; RNA, Messenger | 2023 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |
Pharmacological and Genetic Blockade of
Topics: Animals; Blood Pressure; Carotid Body; Fingolimod Hydrochloride; Hydrogels; Hypertension; Immunosuppressive Agents; Leptin; Male; Mice, Inbred C57BL; Mice, Knockout; Obesity; RNA Interference; TRPM Cation Channels | 2021 |
Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Mammary Neoplasms, Experimental; Mice; Obesity; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Retrospective Studies; Sphingosine; STAT3 Transcription Factor | 2017 |
Targeting the SphK1/S1P/S1PR1 Axis That Links Obesity, Chronic Inflammation, and Breast Cancer Metastasis.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Breast Neoplasms; Cell Line, Tumor; Culture Media, Conditioned; Cytokines; Diet, High-Fat; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Interleukin-6; Lung; Lysophospholipids; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Obesity; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2018 |
Sphingosine-1-phosphate analog FTY720 reverses obesity but not age-induced anabolic resistance to muscle contraction.
Topics: Aging; Animals; Cells, Cultured; Diet, High-Fat; Fingolimod Hydrochloride; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Muscle Contraction; Muscle, Skeletal; Obesity; Random Allocation; Sarcopenia; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators | 2019 |
Modulation of Cell-Mediated Immunity to Suppress High Fat Diet-Induced Obesity and Insulin Resistance.
Topics: Animals; Cyclosporine; Diet, High-Fat; Fingolimod Hydrochloride; Gene Expression Regulation; Immunity, Cellular; Immunosuppressive Agents; Insulin Resistance; Mice, Inbred C57BL; Obesity; Weight Gain | 2016 |
Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Antigens, Differentiation; Carrier Proteins; Cell Size; Diet, High-Fat; Disease Models, Animal; Enzyme Activation; Fingolimod Hydrochloride; Gene Expression Regulation, Enzymologic; Glycogen Synthase Kinase 3; Lipase; Lipolysis; Male; Mice; Mice, Inbred C57BL; Obesity; Perilipin-1; Phosphoproteins; Phosphorylation; Propylene Glycols; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Sphingosine; Sterol Esterase | 2012 |
The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice.
Topics: Animals; Ceramides; Dietary Fats; Fingolimod Hydrochloride; Glucose; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Propylene Glycols; Sphingosine | 2013 |